Dapawin 5 mg (Tablet)
Unit Price: ৳ 16.00 (3 x 10: ৳ 480.00)
Strip Price: ৳ 160.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Dapagliflozin propanediol |
| Company | Beacon pharmaceuticals plc |
Indications
- Adjunct to diet and exercise
- Improves glycemic control
- For adults with type 2 diabetes mellitus
Pharmacology
- Inhibitor of Sodium-glucose co-transporter 2 (SGLT2)
- Reduces reabsorption of filtered glucose
- Lowers renal threshold for glucose (RTG)
- Increases urinary glucose excretion
Dosage & Administration
- Recommended starting dose: 5 mg once daily
- Dose increase to 10 mg once daily for additional glycemic control
- Assessment of renal function recommended before initiation
- Dosing adjustment for patients with renal impairment
- Not established for children and adolescents
Interaction
- May interact with diuretics
- Increase the risk of dehydration and hypotension
- Potential for hypoglycemia with insulin and insulin secretagogues
- Possible interaction with antihypertensives
- Consideration for dosing adjustments with combination therapy
Contraindications
- Known hypersensitivity to Dapagliflozin or excipients
- Severe renal impairment
- End-stage renal diseases
- Patients on dialysis
Side Effects
- Hypotension
- Ketoacidosis
- Acute kidney injury and impairment in renal function
- Urosepsis and pyelonephritis
- Hypoglycemia with concomitant use with insulin and insulin secretagogues
- Genital mycotic infections
- Increases in low-density lipoprotein cholesterol (LDL-C)
- Nasopharyngitis
- Urinary tract infection
- Bladder cancer
Pregnancy & Lactation
- Pregnancy category C
- Limited data on use in pregnant women
- Use during pregnancy only if potential benefit justifies potential risk to fetus
- Not recommended for use during lactation
Precautions & Warnings
- Assessment of volume status and correction of hypovolemia before initiation
- Monitoring for signs and symptoms of hypotension
- Renal function monitoring during therapy
- Consideration for dosing adjustments for hypoglycemia risk
- Caution in patients with a prior history of bladder cancer
- No conclusive evidence of macrovascular risk reduction
Therapeutic Class
- Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors
Storage Conditions
- Store in a cool place (below 30°C)
- Dry place protected from light
- Keep away from the reach of children